December 2023 in “International Journal of Molecular Sciences” Men with early balding showed higher levels of certain genes linked to hair loss and possibly prostate cancer.
October 2006 in “Aging Health” Dutasteride effectively treats benign prostatic obstruction, improves urinary flow, reduces prostate size, and may prevent prostate cancer, but can cause sexual side effects.
April 2012 in “The Journal of Urology” More prostate biopsies increase the chance of finding cancers that may not need treatment.
3 citations,
January 2008 in “Endocrine journal” A new mutation linked to partial Androgen Insensitivity Syndrome and prostate cancer was found in a patient unhappy with their female gender assignment.
April 2012 in “The Journal of Urology” Early baldness increases prostate cancer risk, radiotherapy and surgery have similar second cancer rates, and ALA may reduce prostate cancer risk.
Androgen-modulating drugs do not significantly change the heat sensitivity of prostate cancer cells.
32 citations,
May 2006 in “The Journal of Urology” Using finasteride with TIP extends time off period for prostate cancer patients.
14 citations,
March 2001 in “Psychiatric Services” Older men should openly discuss sexual health with doctors to improve their quality of life.
February 2012 in “Community oncology” The document concludes that accurately identifying leukemia types is crucial, and the risks of cancer from finasteride need careful evaluation against its benefits.
May 1999 in “Drugs & Therapy Perspectives” Finasteride helps increase or maintain hair in most men but can cause sexual side effects and should not be used by women, especially during pregnancy.
26 citations,
March 2006 in “Endocrine, metabolic & immune disorders. Drug targets” This enzyme helps metabolize fatty acids and isoleucine, and could be key in treating neurological diseases and certain cancers.
February 2012 in “Community oncology” Finasteride for hair loss may increase the risk of certain cancers and has side effects; better regulation and education on its use are needed.
16 citations,
January 2003 in “Nuclear Receptor Signaling” Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.
February 2017 in “Cancer Causes & Control” Swedish men with the E213 A-allele of the androgen receptor have a lower risk of prostate cancer.
May 2007 in “The Journal of Urology” Finasteride lowers PSA levels in men, certain factors increase testicular cancer risk, and current guidelines for penile cancer may lead to unnecessary surgeries.
June 2017 in “Journal of The American Academy of Dermatology” Most men with lichen planopilaris had it confirmed by biopsy and often had thyroid issues, sexual dysfunction, or prostate cancer, hinting at a link with hormonal problems.
2 citations,
October 2001 in “Analytical Sciences” A new compound that could treat various androgen-related conditions was created and analyzed.
18 citations,
April 2001 in “Bioorganic & Medicinal Chemistry Letters” The nature of the side chain in RU 58841 derivatives greatly affects its AR affinity, with the N-(iodopropenyl) derivative 13 showing the highest AR binding affinity, suggesting its potential for developing high-affinity radioiodinated AR radioligands.
December 2023 in “Research and reports in urology” A young man with high-grade prostate cancer had successful surgery and good recovery, highlighting the need for awareness in younger men.
45 citations,
May 2012 in “The Journal of Steroid Biochemistry and Molecular Biology” Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.
29 citations,
October 2020 in “eLife” Higher testosterone levels can increase the risk of certain diseases like type 2 diabetes in women and prostate cancer in men, but can also protect against autoimmune diseases and hair loss. It also affects body fat and bone density.
April 2019 in “The Journal of urology/The journal of urology” Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.
7 citations,
October 2017 in “The Prostate” Baldness in men with prostate cancer is linked to higher levels of certain sex hormones, but chest hair density is not.
May 2022 in “Current Enzyme Inhibition” Compound 7b is a promising candidate for treating benign prostatic hyperplasia and prostate cancer.
57 citations,
April 2009 in “The Journal of Steroid Biochemistry and Molecular Biology” Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.
280 citations,
May 2005 in “Andrology” Testosterone treatment for older men can have short-term benefits, but long-term risks are unclear, requiring careful evaluation and monitoring.
October 2008 in “The Journal of Urology” Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.
Men with early balding may have a higher risk of prostate issues, and surgery for prostate cancer has a slight survival benefit over radiation.
44 citations,
October 2010 in “BJUI” 5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
March 2009 in “The Journal of Urology” Low dose finasteride causes only small changes in PSA levels in older men with BPH.